https://scholars.lib.ntu.edu.tw/handle/123456789/536019
標題: | Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection | 作者: | CHI-TAI FANG PEI-JER CHEN Chen M.-Y. CHIEN-CHING HUNG SHAN-CHWEN CHANG Chang A.-L. DING-SHINN CHEN |
公開日期: | 2003 | 出版社: | Elsevier | 卷: | 39 | 期: | 6 | 起(迄)頁: | 1028-1035 | 來源出版物: | Journal of Hepatology | 摘要: | Background/Aims: The optimal strategy to prescribe highly active antiretroviral therapy (HAART) in patients infected with both hepatitis B virus (HBV) and human immunodeficiency virus (HIV) remains unsettled. This study aimed to compare the HBV dynamics between HBeAg-positive and HBeAg-negative coinfected patients treated with lamivudine-containing HAART. Methods: We retrospectively analyzed the serial changes of plasma HBV DNA levels in 24 HBsAg-positive HIV-infected patients who entered the HAART program. A polymerase chain reaction-based assay, capable of quantifying as few as 400 HBV copies/ml, was used. The median follow-up time was 18 months. Results: HAART containing lamivudine 300 mg/day effectively suppressed plasma HBV-DNA to 10-3-10-5-fold of the baseline levels, but a multi-phasic decay of HBV DNA was observed. The later phases became flat, as a persistent residual HBV viremia, in eight of the studied 10 HBeAg-positive patients; in contrast, residual HBV viremia was not observed in the 10 HBeAg-negative patients studied (8/10 vs. 0/10, P = 0.0007, Fisher's exact test). HAART without lamivudine did not suppress plasma HBV DNA levels in the remaining four patients. Conclusions: HAART containing lamivudine 300 mg/day effectively suppress HBV replication in HBeAg-negative HIV/HBV-coinfected patients. Nevertheless, residual HBV replication persisted in most HBeAg-positive coinfected patients. ? 2003 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984538372&doi=10.1016%2fS0168-8278%2803%2900416-1&partnerID=40&md5=1f68cf103fee7594fa23f351c40cef20 https://scholars.lib.ntu.edu.tw/handle/123456789/536019 |
ISSN: | 0168-8278 | DOI: | 10.1016/S0168-8278(03)00416-1 | SDG/關鍵字: | antiretrovirus agent; deoxycytidine; didanosine; hepatitis B(e) antigen; indinavir; lamivudine; saquinavir; stavudine; virus DNA; zidovudine; adult; article; controlled study; DNA degradation; drug efficacy; follow up; Hepatitis B virus; highly active antiretroviral therapy; human; Human immunodeficiency virus infection; major clinical study; male; nonhuman; persistent infection; polymerase chain reaction; priority journal; retrospective study; viremia; virus inhibition |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。